VC Fund Dossiers

Redmile is one of the most respected healthcare crossover funds in the game, but they're essentially a hedge fund with venture capital aspirations. Jeremy Green built his reputation as a sharp healthcare analyst at Citi before launching Redmile, and his European perspective on biotech gives him edge that most US-centric funds lack. The good news: they have real money ($6.5B AUM), genuine expertise, and will stick with you through public markets - rare in today's VC world. The reality check: this isn't your typical founder-friendly VC. They're investors, not advisors, and they evaluate opportunities with hedge fund rigor. If your biotech has solid science and a clear path to meaningful revenue, they're fantastic. If you need hand-holding or warm introductions to potential customers, look elsewhere.

Ridge is one of the more authentic enterprise-focused funds out there - they actually mean it when they say "revenue-first" and aren't chasing the latest AI hype cycle just for vanity. Founders rave about partners like Brendan Baker who "doesn't waste entrepreneurs' time" and delivers real value through feedback and connections. Their "Ridge Revenue Network" of 100+ Fortune 500 CXOs isn't just marketing fluff - they actually write customer intro commitments into term sheets. Gil Penchina brings serious operating chops and a massive angel network, while Alex Rosen has a track record of picking winners early. The downside? As a "focused fund" they're super selective and only back companies where their excitement matches the founder's - so if you don't click personally, you're out.

Rittenhouse is the anti-unicorn fund that actually makes sense in today's market. Saul Richter explicitly says he's "not interested in searching for so-called unicorns" and is "more interested in exits of $35 to $75 million." This is refreshingly honest - they're not chasing billion-dollar fantasies, they're building a business around achievable outcomes. With "total portfolio exit values exceeding $3 billion," they've actually delivered returns. The team upgrade with David Nevas (Edison Partners pedigree) and Sushma Rajagopalan (actual CEO experience) shows they're serious about scaling beyond their Philly roots. They acknowledge that "our region has yet to scale up its corresponding growth capital base" but see opportunity in being "location in the heart of Philly means we have some of the best and brightest in the country right at our doorstep." The founder testimonials are genuinely positive - not just generic praise.